Jasper Therapeutics, Inc. (JSPR), a biotechnology company focused on treating mast cell-driven diseases, is set to present promising preclinical data on its novel antibody therapy, briquilimab, at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Boston.
The data underscores briquilimab’s effectiveness in targeting c-Kit (CD117), a key receptor in CSU, CIndU, and asthma.
CHECK THIS OUT: Pfizer Beats Q3 Forecasts, Eyes Growth in Weight-Loss Market.
Promising Preclinical Data Demonstrates Briquilimab’s Targeted Potency
Dr. Wendy Pang, Jasper’s Senior VP of Research, shared her optimism about briquilimab’s effectiveness based on the findings.
She noted lab and animal data confirm briquilimab’s strong binding to c-Kit, effectively reducing mast cells.
These results provide valuable support for the therapy’s potential in tackling complex inflammatory responses associated with CSU, CIndU, and asthma.
The presentations will showcase multiple aspects of the novel antibody therapy’s performance, including its tolerability and ability to deplete tissue-resident mast cells in non-human primates, as well as its inhibition of stem cell factor (SCF)/c-Kit signaling and mast cell degranulation in primary human mast cells.
The company will present this data at Exhibit Hall A, showcasing briquilimab’s impact on mast cell survival and signaling.
Briquilimab’s Expanding Role in Mast Cell and Stem Cell Diseases
The company’s antibody briquilimab blocks stem cell factor binding to c-Kit, disrupting survival signals and depleting mast cells.
The therapy is in trials for CSU, CIndU, and as a conditioning agent for rare diseases, including SCD and FA.
The novel antibody therapy has shown a strong safety profile and early efficacy in over 160 participants across CIndU, SCID, AML, and MDS.
Jasper Therapeutics aims to meet significant unmet needs in mast and stem cell diseases through its briquilimab program.
The ACAAI presentations will be available on the ACAAI website and Jasper’s Investor Relations page, showcasing briquilimab’s potential.
READ ALSO: Visa Q3 2024: Revenue Reaches $8.9B, Driven by Cross-Border Gains and Super Micro Shares Drop 30% as Auditor Resigns Over Concerns.
